The phase III BREAKWATER trial evaluated early integration of targeted therapy with encorafenib plus cetuximab in combination with chemotherapy for patients with previously untreated BRAF V600E–mutated metastatic colorectal cancer (mCRC). Results demonstrated significantly improved response rates and progression-free survival (PFS) compared with standard chemotherapy, supporting FDA traditional approval of this targeted combination in the frontline setting.
Drug Profile & Mechanism
- Profile:
- Encorafenib (Braftovi) is an oral BRAF inhibitor administered in combination with the epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab (Erbitux).
- Mechanism:
- Encorafenib selectively inhibits mutated BRAF V600E kinase activity, blocking downstream MAPK pathway signaling responsible for tumor proliferation. Because BRAF inhibition alone induces compensatory EGFR activation in colorectal cancer, concurrent EGFR blockade with cetuximab prevents pathway reactivation, resulting in sustained antitumor activity.
- Target Population:
- Adults with metastatic colorectal cancer harboring a BRAF V600E mutation in the first-line treatment setting.
- Delivery System:
- Encorafenib: oral capsule
- Cetuximab: intravenous infusion
- Administered alongside modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy
- Treatment Schedule:
- Encorafenib is administered once daily orally with scheduled cetuximab infusions and chemotherapy delivered per standard dosing cycles until disease progression or unacceptable toxicity.
BREAKWATER Study Design (NCT04607421)
- Study Design: Global, randomized, open-label phase III trial evaluating the integration of targeted therapy into first-line treatment for BRAF V600E–mutated mCRC.
- Study Objective: To determine whether adding encorafenib plus cetuximab to standard chemotherapy improves clinical outcomes compared with chemotherapy alone.
- Participants: A total of 479 patients with previously untreated BRAF V600E–mutated metastatic colorectal cancer were randomized in the phase III portion of BREAKWATER, including 236 patients assigned to encorafenib plus cetuximab with mFOLFOX6 (Arm B, investigational) and 243 patients assigned to chemotherapy-based control therapy (Arm C).
- Primary Endpoint: Progression-free survival (PFS) assessed by blinded independent central review.
- Secondary Endpoints:
- Overall survival (OS)
- Objective response rate (ORR)
- Duration of response (DoR)
- Safety and tolerability
Efficacy outcomes supporting approval are summarized below.
Study Outcomes
- Primary Endpoint:
- The addition of encorafenib plus cetuximab to chemotherapy significantly improved progression-free survival (PFS) compared with standard chemotherapy alone, demonstrating superior disease control in this historically poor-prognosis population.
- Median PFS was 12.8 months (95% CI, 11.2–15.9) with encorafenib plus cetuximab and mFOLFOX6 compared with 7.1 months (95% CI, 6.8–8.5) with control therapy (hazard ratio [HR], 0.53; 95% CI, 0.41–0.68; P < .0001).
- The progression-free survival benefit was observed consistently across evaluated patient subgroups.
- Key Secondary Endpoints:
- Objective response rate was 61% with encorafenib-based therapy compared with 40% in the control arm (P = .0008).
- Responses occurred earlier and were more durable than with chemotherapy alone.
- Overall survival favored the combination regimen, supporting early targeted pathway inhibition in the frontline setting.
Regulatory Milestones
- Approval Date: February 24, 2026
- Regulatory Pathway: Traditional Approval
- Approval Review: FDA approval was supported by efficacy and safety findings from the phase III BREAKWATER trial demonstrating clinically meaningful improvement in outcomes for patients with BRAF V600E-mutated metastatic colorectal cancer.
Safety
- Overall Adverse Effects (AEs):
- Common adverse reactions included gastrointestinal toxicity, dermatologic reactions, fatigue, anemia, and infusion-related reactions consistent with known profiles of BRAF and EGFR inhibition combined with chemotherapy.
- Severity of Toxicity:
- Grade ≥3 AEs occurred in a notable proportion of patients but were generally manageable with supportive care and dose modification.
- Treatment Modifications:
- Dose interruptions, reductions, and supportive care measures were effective in managing treatment-related toxicities.
- Overall, the safety profile was consistent with previously established toxicities of encorafenib and cetuximab-based therapy and considered manageable with appropriate monitoring.
Despite increased toxicity associated with combination targeted therapy and chemotherapy, adverse events were generally manageable with dose modification and standard supportive care measures.
Development Status
- Current Status: The combination of encorafenib plus cetuximab with chemotherapy (mFOLFOX6) has received FDA traditional approval for the first-line treatment of adults with BRAF V600E-mutated metastatic colorectal cancer.
- Prescribing information: Available at Drugs@FDA
- Side Effect Reporting: Healthcare professionals are encouraged to report negative side effects to the FDA
Sources:
U.S. Food and Drug Administration. (2026, February 24). FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-encorafenib-metastatic-colorectal-cancer-braf-v600e-mutation
ClinicalTrials.gov. (2026). BREAKWATER: A study of encorafenib plus cetuximab with or without chemotherapy in participants with BRAF V600E–mutant metastatic colorectal cancer (NCT04607421). U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT04607421
